8 July 2024 - Voretigene neparvovec (Luxturna) was accepted for the treatment of adults and children with an extremely rare inherited eye condition called inherited retinal dystrophy. 

It has been available for use as part of the ultra-orphan pathway, since 2020, while further evidence on its effectiveness was collected. Following reassessment, it has now been accepted by SMC for routine use.

Read SMC press release